Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Why Isn't Biogen Stock Soaring After This Major FDA Approval?
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
Submitted by
admin
on July 13, 2023 - 10:16am
Source:
Motley Fool
News Tags:
Biogen
Eisai
Leqembi
Alzheimer's disease
Headline:
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
snippet:
The FDA gave full approval for Alzheimer's drug Leqembi in July.
Despite the positive news, Biogen's stock didn't take off.
That's because the company still faces some significant headwinds.
Do Not Allow Advertisers to Use My Personal information
